Bio: Weimin Chen is an Associate Scientific Director in the Nonclinical Safety Portfolio Scientific Leadership team at Johnson & Johnson Innovative Medicine (J&J IM), where she is responsible for providing leadership for nonclinical safety strategy and execution to discovery and development teams across therapeutic areas and modalities from portfolio entry to registration. Prior to joining J&J IM in 2022, Dr. Chen was a Principal Scientist in Nonclinical Safety Portfolio Leadership team at Bristol-Myers Squibb (BMS) working as a project toxicologist on development teams primarily in Immuno-oncology, Immunoscience, and Neuroscience therapeutic areas. Dr. Chen received her dual PhD degree in Environmental & Integrative Toxicological Sciences, and Microbiology & Molecular Genetics from Michigan State University in 2014. She is author/co-author of 13 peer-reviewed research articles and has over 25 abstracts presented at multiple scientific conferences. Dr. Chen has been actively involved in Society of Toxicology (SOT) activities since she was a graduate student in 2009. During that time, she was the recipient of several scholarship awards from Women in Toxicology and AACT Special Interest Groups of SOT. Over the years, she has served in multiple positions, including student representative, councilor, and secretary for American Association of Chinese in Toxicology (AACT) Special Interest Group, programming committee for Immunotoxicology Specialty section, and graduate student leadership committee and programming subcommittee of SOT. In addition, Dr. Chen has served on Immunotoxicology Technical Committee and working groups for Health and Environmental Sciences Institute (HESI) and The International Consortium for Innovation and Quality in Pharmaceutical Development (IQ) Preclinical Safety Leadership Group (DruSafe) and engaged in the toxicology course series at universities to educate and mentor graduate students.